TB-500 vs Thymosin Beta-4
Thymosin Beta-4 Fragment · Thymic Peptide
Here is how these two compounds compare, based on published research, not marketing claims.
TB-500
The synthetic 4-amino-acid fragment of the thymosin beta-4 active site; the commercially available research peptide form.
Thymosin Beta-4
The full 43-amino-acid endogenous protein; the parent molecule with the complete structural context and broader published research.
TB-500
1050 studies
13 human trials
Not FDA-Approved
Thymosin Beta-4
1038 studies
13 human trials
Not FDA-Approved
What it does
TB-500
Typically a synthetic 4-amino-acid fragment of thymosin beta-4's active region (Ac-SDKP, the first four residues of the 43-amino-acid parent molecule), though commercial products labeled TB-500 vary in actual composition. Marketed as if interchangeable with full-length Tβ4, but the published human research is on the parent peptide, not the fragment. The mechanism described in animal studies (mobilization of repair cells through actin sequestration) is shared, but the evidence base for TB-500 specifically is a fraction of what exists for thymosin beta-4.
Thymosin Beta-4
Sequesters actin inside cells, which allows cells to migrate toward damaged tissue and begin repair. The full-length parent molecule that TB-500 is derived from. Found naturally throughout the body at high concentrations.
How it works
TB-500
A copy of a fragment of a natural protein called Thymosin Beta-4. It works on actin, the scaffolding cells use to crawl through tissue. By turning up that scaffolding-rebuild process, the body's repair cells can migrate to where they're needed, and inflammatory signals get dialed down along the way.
Thymosin Beta-4
Thymosin Beta-4 is a 43-amino-acid peptide that binds monomeric actin (G-actin), preventing it from polymerizing prematurely. By controlling when and where actin assembles, Thymosin Beta-4 enables the cytoskeletal reorganization cells need to move, divide, and form new blood vessels. This mechanism drives tissue repair through cell migration, angiogenesis, and anti-inflammatory signaling. TB-500, the commercially available research peptide, is a 4-amino-acid synthetic fragment corresponding to the active site of Thymosin Beta-4, not the full molecule.
How often
TB-500
In studies, given as a twice-weekly shot under the skin. The compound stays active in the body longer than BPC-157, which is why dosing is less frequent in protocols.
Thymosin Beta-4
In published research, Thymosin Beta-4 has been studied in animal models of wound healing, cardiac injury, corneal repair, and neurological damage. No FDA-approved product exists for the full-length molecule. Clinical development programs for ophthalmic indications (RGN-259) have been conducted but have not yet resulted in FDA approval.
How strong
TB-500
Body-wide. Unlike BPC-157's local action, TB-500's signal works wherever cells are migrating, which is anywhere repair is happening.
Thymosin Beta-4
Extensive preclinical data across multiple tissue types: cardiac, dermal, corneal, and neurological repair models. The actin-sequestering mechanism is well-characterized biochemically. The RGN-259 ophthalmic program generated human safety and preliminary efficacy data. TB-500, the fragment form, is more widely available in research peptide markets than full-length Thymosin Beta-4.
Main tradeoff
TB-500
Bigger total research base than BPC-157, including more human studies. The catch: most of that broader work is on the parent protein, Thymosin Beta-4, not the TB-500 fragment specifically. The two don't always behave the same way.
Thymosin Beta-4
The full-length Thymosin Beta-4 molecule has more preclinical data than TB-500 but is harder to source and more expensive. TB-500, the fragment, is widely available but represents only the active site, not the complete signaling molecule. Whether the fragment recapitulates the full molecule's effects in all tissue contexts is not definitively established. Neither form is FDA-approved for any therapeutic indication.
Best for
TB-500
- Research on systemic recovery across multiple sites
- Research into a body-wide repair signal rather than a localized one
- Research using twice-weekly dosing
Thymosin Beta-4
- Research comparing full-length Thymosin Beta-4 signaling versus the TB-500 active fragment
- Research on actin-sequestering mechanisms in tissue repair and cell migration
- Research on endogenous wound-healing peptides and their therapeutic potential
How to choose
A good fit for TB-500
- Research using the commercially available fragment form as a practical research tool
- Research on whether the active site fragment recapitulates the full molecule's effects
- Research contexts where sourcing the full-length 43-AA protein is impractical
A good fit for Thymosin Beta-4
- Research requiring the complete signaling context of the full-length parent molecule
- Research building on published thymosin beta-4 literature (most academic papers use the full molecule)
- Research on ophthalmic applications where RGN-259 (full-length) has human clinical data
Consider both across time
TB-500 and thymosin beta-4 share the same core mechanism (actin sequestration enabling cell migration), but differ structurally and in commercial availability. When published research says 'thymosin beta-4,' it means the full 43-amino-acid protein. When peptide vendors say 'TB-500,' they mean the synthetic fragment. Whether the fragment fully recapitulates the parent molecule's effects in all tissue contexts is an open scientific question. The full molecule has more published data; the fragment is what most people can actually obtain.
Dosing should be determined by a qualified physician who can evaluate individual circumstances. PSI does not provide personalized dosing guidance.
Official dosing references
- DailyMed(NIH drug labels)
- ClinicalTrials.gov
- PubMed
For readers who want the biology: here is the pathway each compound uses to signal the body. This section is optional. The comparison above covers the practical differences.
▶See the biology
- Tissue Repair
- Tissue Repair connects to Actin Regulation
- Actin Regulation promotes Cell Migration
- Cell Migration connects to Cytokine Reduction
- Cytokine Reduction connects to Cell Arrival at Injury
- G-Actin Sequestration
- G-Actin Sequestration enables Cell Migration
- G-Actin Sequestration promotes Angiogenesis
- G-Actin Sequestration activates Hair Follicle Stem Cell Activation
- Cell Migration connects to Tissue Repair; Angiogenesis connects to Tissue Repair
- Hair Follicle Stem Cell Activation connects to Tissue Regeneration
TB-500 mimics the active site of thymosin beta-4, sequestering G-actin to enable cell migration and tissue repair.
Thymosin beta-4 is the full 43-amino-acid parent molecule with actin sequestration plus additional signaling domains beyond the active site.
Research Evidence
The published literature predominantly studies the full-length thymosin beta-4 molecule, not the TB-500 fragment. Thymosin beta-4 has published human safety data from the RGN-259 ophthalmic development program plus extensive animal data across cardiac, dermal, corneal, and neurological repair models. TB-500 has primarily animal model data (cardiac injury, wound healing) with limited published human data. The active site mechanism is shared, but whether the fragment's pharmacological profile matches the full molecule's across all contexts is not definitively established.
- 1.
For evidence-based evaluation, Thymosin Beta-4 has the actual published research.
- 2.
For practical availability, TB-500 is more widely available and cheaper to produce.
- 3.
If reading research, check whether the study used Thymosin Beta-4 (full protein) or the TB-500 fragment, most used the full protein.
- 4.
The fragment likely retains the core actin-regulatory activity, but this assumption has not been rigorously validated.
Key Limitations
- •Studies cited for TB-500 usually used the full Thymosin Beta-4 protein.
- •Whether the fragment has identical therapeutic properties to the full protein is assumed, not proven.
- •Neither has achieved FDA approval.
- •Head-to-head comparison of the fragment vs full protein does not exist.
Community Discussion
PSI monitors discussions across peptide research and biohacking communities. These are reported experiences, not clinical evidence.
TB-500
"TB-500 is the best peptide for systemic recovery after surgery"
Plausible but unproven
"Stacking TB-500 with BPC-157 covers both local and systemic healing"
Plausible but unproven
"It healed my torn rotator cuff without surgery"
Anecdotal only
Thymosin Beta-4
"Thymosin Beta-4 is the same thing as TB-500"
Partially accurate
"There's an eye drop version in clinical trials"
Supported by evidence
Safety Comparison
Both are derived from the same endogenous protein found naturally at high concentrations throughout the body. Thymosin beta-4 has human safety data from the RGN-259 clinical development program. TB-500 has a favorable animal safety profile. Neither is FDA-approved. The safety profiles are expected to overlap given the shared mechanism, but the fragment lacks the dedicated human safety characterization the full molecule has received.
TB-500
Limited safety data specific to the fragment. Inferred from Thymosin Beta-4 research. Not FDA-approved.
Thymosin Beta-4
More safety data than TB-500. Clinical trials conducted for corneal healing and cardiac repair. Generally well-tolerated in published studies.
What the Research Suggests
TB-500 is a commercially convenient form of Thymosin Beta-4. The research mostly supports the full protein. Applying full-protein data to the fragment is reasonable but not rigorous.